****

**National Health Innovation Centre Singapore**

**Innovation to Develop (I2D) Grant**

**Application Form**

|  |  |
| --- | --- |
| NHIC Reference No. |  |
| PRINCIPAL INVESTIGATOR |  |
| HOST INSTITUTION |  |
| HEALTHCARE CLUSTER |  |

This form is used by applicants applying for NHIC I2D Grant administered by National Health Innovation Centre Singapore. For more information about the grant scheme, please visit [nhic.sg](http://www.nhic.sg).

|  |  |
| --- | --- |
| **Eligibility Criteria** | * The Principal Investigator must hold a primary appointment in and be salaried by public healthcare institution or academic medical school in Singapore. Project teams must have strong clinical representation. Collaborations with industry are encouraged if they strengthen the proposal. All applications are considered based on merit and eligibility is not limited to NMRC-funded research. * Only one re-submission is allowed. |
| **Guidelines** | * Complete the latest version of NHIC Grant Application Form (NHIC-I2D-FORM-1). * Use Arial font size 11 and single spacing for all text. * Complete all sections in the grant application form; indicate “**NA**” where not applicable. |
| **Submission Details** | * All **applications** must be **fully endorsed** and submitted electronically by the designated Research/Innovation Offices from the respective Healthcare Cluster (as listed in the table below) to the NHIC Grant Secretariat.  |  |  | | --- | --- | | **Healthcare Cluster** | **Designated Research/Innovation Office** | | National Healthcare Group | NHG Group Research | | National University Health System | NUHS Research Office | | Singapore Health Services | SingHealth Office of Intellectual Property (SHIP) | | Duke-NUS Medical School | Duke-NUS Medical School Sponsored Research Department | | Lee Kong Chian School of Medicine | NTU Research Support Office | | Yong Loo Lin School of Medicine | NUHS Research Office |  * Please submit the following softcopies documents to Grant Secretariat at [grant@nhic.cris.sg](mailto:grant@nhic.cris.sg) by **Closing Date, 5pm**, with the subject headed “NHIC-I2D\_(Name of PI’s Healthcare Cluster)\_Name of PI’s Institution)”. *NB: Host Institution internal submission deadline may apply, please check with your Research Office for more details.*  1. i) a single Microsoft Word document, without signatures, and ii) a single PDF document, with signatures. Please name the document in the following format.   NHIC-I2D\_Host Institution\_PI’s Name   * The application may be rejected for the following reasons:  1. Incomplete application e.g. missing signatures; sections left blank, missing CVs, sections removed. 2. Obsolete application form. 3. Late submission or revision to the submitted application will not be accepted after the closing date. |

**Important:** Relevant privileged or confidential information should be disclosed to help convey a clear understanding of the project. However, such information must be clearly marked in the proposal. All information is treated in confidence. The information is furnished to the National Health Innovation Centre Singapore (NHIC) with the understanding that it shall be used or disclosed for evaluation, reference and reporting purposes*.* If your application is not successful, this form will be destroyed after the retention period deemed as appropriate by NHIC.

|  |
| --- |
| 1. **CATEGORY OF PROPOSAL** |

|  |  |
| --- | --- |
| New Submission  *Please specify* *if the applications/projects were funded under NHIC Joint MedTech or I2P Grant Scheme and*  *provide details:*    Application that has been previously submitted for NHIC research grants  (Application ID: NHIC-I2D-     )  *Please approach your NHIC Cluster Manager for advice before submitting the current application.* | |
| *Please indicate the relevant category:* | |
| **MedTech**  Devices  Diagnostics  Health IT & Software | **BioPharma**  In Vitro Diagnostics / Companion Diagnostics  Others: Please provide  Therapeutics: Please provide |

|  |
| --- |
| 1. **APPLICANTS’ INFORMATION**   *Please note the definitions of a Principal Investigator (PI), Co-Investigator (Co-I) and Collaborator, as indicated in the footnote. The terms of collaboration with overseas research institutions and companies must conform to NHIC’s & NMRC’s existing policies.* (\*please add more rows if required) |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name | Role in Project (e.g. Principal Investigator[[1]](#footnote-1), Co-I[[2]](#footnote-2), Collaborator[[3]](#footnote-3) [[4]](#footnote-4) | Host Institution[[5]](#footnote-5) | % Effort within Project[[6]](#footnote-6) | % Effort Within Own Work Commitments[[7]](#footnote-7) |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  | **Total** | **100%** |  |

|  |
| --- |
| **2b. Outline below the role of each team member and what expertise they bring to the Project.** |

|  |
| --- |
| 1. **TITLE OF PROJECT *(Limit to 15 words****)* |

|  |
| --- |
| 1. **FIELD OF PROJECT**   *Please complete the Health Research Classification (HRC) System below.* |

|  |  |
| --- | --- |
| **4a. Health Category**  *You may select up to 5 categories from below. Please use minimum number of codes to reflect main focus of the research* | |
| Blood  Cancer  Cardiovascular  Congenital Disorders  Ear  Eye  Infection  Inflammatory and Immune System  Injuries and Accidents  Mental Health  Metabolic and Endocrine | Musculoskeletal  Neurological  Oral and Gastrointestinal  Renal and Urogenital  Reproductive Health and Childbirth  Respiratory  Skin  Stroke  Generic Health Relevance  Other |

|  |  |
| --- | --- |
| **4b. Project Activity Code**  *Please select up to 2 sub-codes from the following, eg, 2.1.* | |
| **1 Underpinning Research**  1.1 Normal biological development and functioning  1.2 Psychological and socioeconomic processes  1.3 Chemical and physical sciences  1.4 Methodologies and measurements  1.5 Resources and infrastructure (underpinning)  **2 Aetiology**  2.1 Biological and endogenous factors  2.2 Factors relating to physical environment  2.3 Psychological, social and economic factors  2.4 Surveillance and distribution  2.5 Research design and methodologies (aetiology)  2.6 Resources and infrastructure (aetiology)  **3 Prevention of Disease and Conditions, and Promotion of Well-Being**  3.1 Primary prevention interventions to modify  behaviours or promote well-being  3.2 Interventions to alter physical and biological  environmental risks  3.3 Nutrition and chemoprevention  3.4 Vaccines  3.5 Resources and infrastructure (prevention)  **4 Detection, Screening and Diagnosis**  4.1 Discovery and preclinical testing of markers and  technologies  4.2 Evaluation of markers and technologies  4.3 Influences and impact  4.4 Population screening  4.5 Resources and infrastructure (detection)  **5 Management of Diseases and Conditions**  5.1 Individual care needs  5.2 End of life care  5.3 Management and decision making  5.4 Resources and infrastructure (disease management) | **6 Development of Treatments and Therapeutic Interventions**  6.1 Pharmaceuticals  6.2 Cellular and gene therapies  6.3 Medical devices  6.4 Surgery  6.5 Radiotherapy  6.6 Psychological and behavioural  6.7 Physical  6.8 Complementary  6.9 Resources and infrastructure (development of  treatments)  **7 Evaluation of Treatments and Therapeutic Interventions**  7.1 Pharmaceuticals  7.2 Cellular and gene therapies  7.3 Medical devices  7.4 Surgery  7.5 Radiotherapy  7.6 Psychological and behavioural  7.7 Physical  6.8 Complementary  6.9 Resources and infrastructure (evaluation of  treatments)  **8 Health and Social Care Services Research**  8.1 Organisation and delivery of services  8.2 Health and welfare economics  8.3 Policy, ethics and research governance  8.4 Research design and methodologies  8.5 Resources and infrastructure (health services) |

|  |
| --- |
| 1. **ABSTRACT**   In less than **300 words**, describe in lay terms the aims, hypotheses, methodology and approach of the project proposal including its clinical impact. The abstract must be self-contained so that it can serve as a succinct and accurate description of the project proposal understood by a non-scientific/medical audience. **Note that the abstract may be disclosed to other funding agencies. Please ensure the abstract is non-confidential.** |

|  |
| --- |
| 1. **PROJECT PROPOSAL**   ***In no more than 15 pages*** *(page limit excludes the pictures, tables, CV section and reference section), please*  *complete the following sections in the project proposal.* |
| **6.1. Background & Clinical Need**   * *Describe the background and the significance of the clinical need which the Technology will address.* * *Describe the current approaches to the clinical need and their shortcomings.* * *Who are the target patients? What is the incidence and/or prevalence? What is the total amount spent per year to address the problem faced by these target patients?* |

|  |
| --- |
| **6.2. Description and Impact of the Technology**  *Give a concise description of the proposed Technology covering the following areas:*   * + - *Describe the Technology and how it works.*     - *Detail the preliminary studies you have undertaken using the Technology.*     - *Why is the Technology the best solution for the clinical need?*     - *How will the Technology improve the patient experience and clinical outcomes?*     - *How will the Technology reduce healthcare system costs?*     - *Define the regulatory strategy of the proposed Solution for entry into the first major market* |

|  |
| --- |
| **6.3. Uniqueness & Competitive Analysis of Solution**   * *Identify competing technologies and how this Technology is superior.* * *Outline the differentiating factor(s) of the Technology and the reason that industry would find the Technology attractive.* |

|  |
| --- |
| **6.4. Clinical Workflow & Patient Journey Mapping**   * + - *What is the current clinical workflow and what is the anticipated workflow if the proposed solution is adopted?*     - *What is the current patient journey and where does the proposed solution fit into the cycle of care?* |

|  |
| --- |
| **6.5. Technology Development Plan**   * + - *Describe in detail the Development Plan for the Technology under this funding.*     - *Highlight any technical challenges of the proposed Development Plan. What is the contingency plan where the technical challenges cannot be overcome?*     - *Describe the methods and management of the collaboration i.e. who will take the lead for each area, a plan for regular meetings etc.*     - *Detail any agreements that would need to be put in place prior to starting the Development Plan.* |

|  |
| --- |
| **6.6. Commercialisation Plan**   * *Articulate a clear commercialisation plan for the Technology (for example: out-licensing, the formation of new commercial enterprises, co-development with industry funding (short and long term). Endorsements by potential commercial partners or investors in the project are encouraged).* |

|  |
| --- |
| **6.7. Intellectual Property Management**   * + *Provide details of the relevant Background IP for the Technology. Specifically address: i) ownership ii) any agreements/licences covering the Background IP.*   + *Briefly describe any Foreground IP likely to be generated from the project.*   + *Describe how the Team intends to manage and exploit the IP it has filed/or intends to file.*   + *Provide a description of the Team’s track record of IP generation and commercialisation e.g. list of patents filed (status), licences, spin-off companies etc.* |

|  |
| --- |
| **6.8. Health Economics Outcomes**   * + *Provide details of the key benefits that will be brought to Singapore under NHIC grant. Specifically address:* * *Please describe the clinical application(s), direct and/or potential, of the project which improves clinical service or healthcare outcomes of the nation. Outcomes may include:*   + *Improvement of medical practices*   + *Improvement of cost-effectiveness of healthcare delivery (i.e. efficiency and/or affordability)* * *Please describe the potential impact that the proposed project may have on patient-related outcomes, in terms of reducing the mortality and morbidity of any particular disease burden.* * *Please indicate if the outcome(s) of the project has the potential to be implemented or adopted into healthcare policy of practice.* *If yes, please describe the specific area(s) and how important it is or they are clinically.* * *Please describe the specific areas of clinical importance if the project produced outcomes that can be implemented or adopted into the healthcare policy of practice.* |

|  |
| --- |
| **References:** |

|  |
| --- |
| 1. **ETHICAL CONSIDERATIONS AND CONTAINMENT**   Fund disbursement is subjected to ethics approval if the project involves any of the below. |

|  |  |  |  |
| --- | --- | --- | --- |
| *Please check the box Yes or No if programme involves any of the following:* | | | Please declare the participating institutions where study requiring ethics approval is conducted: |
| a) | Human Subject | Yes  No |  |
| b) | Use of Human Material/Animal Tissues or Cells from Primary Donors (i.e. subject/volunteers recruited for project) | Yes  No |  |
| c) | Use of Commercially Available Human Material/Animal Tissues or Cells | Yes  No |  |
| d) | Animal Experimentation | Yes  No |  |
| e) | Requirement for Containment | Yes  No |  |
| f) | Multi-centre trial(s) | Yes  No |  |
| A copy of the ethics approval is attached | | Yes  No |  |

|  |
| --- |
| 1. **Budget/Justifications for Budget Requested**   List the budget of the funding requested in the format below and provide the relevant justifications. Please refer to Guidelines for the Management of MOH/NMRC (Grantor) Funding Programmes[[8]](#footnote-8). NHIC will fund up to S$300,000 (inclusive of maximum 30% indirect costs) for a duration of 12 months. |

|  |
| --- |
| **8.1 Manpower**  Budget for all the manpower required for the project including part-time personnel and those to be shared with other projects. State whether they are existing personnel in your institution or new staff to be recruited. Please use salary scales provided by the Institution as a reference. The cost should include annual increments, National Service increment, staff welfare, medical and other related benefits as per the Human Resource policies of your institution. **Please note that a Co-I and collaborator cannot be supported under Manpower**. |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Staff Category** | **Employing Institution** | **Existing/New** | **Pax** | **Justification** | **Total Cost** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **Total** | | | | |  |

|  |
| --- |
| **8.2 Equipment**  *Please budget for all scientific equipment you need to purchase to directly carry out the project. Indicate sharing of equipment with other projects, if any. For equipment costing more than $70,000 per item, indicate the estimated utilisation of the equipment (e.g. 70% usage throughout the project period, and etc.).* |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Qty | Equipment | Estimated Utilization Rate for Equipment more than $70,000 (to be justified) | Justification | Total Cost |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  | Total |  |

|  |
| --- |
| 8.3 Other Operating Expenses (OOE)  This covers other expenses directly related to the project such as the purchase of animals, consumables, laboratory manuals, literature searches, and maintenance of equipment. |

|  |  |  |
| --- | --- | --- |
| Item/Description | Justification | Total Cost |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| **Total** | |  |

|  |
| --- |
| 8.4 Overseas Travel  Conference travel will be funded only if a presentation or an article is presented and is capped at $6,000 per trip per person per requested year. Total Overseas Travel expenses shall not exceed $12,000 per project. The presentation or article must be directly related to the project and NHIC’s support must be acknowledged. Travel for commercialisation activities will also be considered by NHIC on a case-by-case basis. NB: Virement into Overseas Travel is not permitted during the grant. |

|  |  |  |
| --- | --- | --- |
| Item Description | Justification | Total Cost |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
| Total | |  |

|  |
| --- |
| 8.5 Indirect Research Cost (IRC)  Indirect research cost is provided to Host Institutions, up to a maximum of 30% of the direct costs. |

|  |  |
| --- | --- |
| Item Description | Total Cost |
|  |  |
|  |  |
| Total |  |

|  |  |
| --- | --- |
| **Total Direct Costs:**  **(Manpower + Equipment + Other Operating Expenses + Overseas Travel)** | S$ |
| **Grand Total:**  **(Total Direct Costs + Indirect Costs)** | S$ |

|  |
| --- |
| **9. MILESTONES/TIMELINE**  *Provide the timeline and proposed milestones for the proposal. Detail reasonable 6-month and 1-year benchmarks for success.*  *Shade the appropriate box(es) to indicate the month that a particular milestone is expected to be met. You can add or delete rows as appropriate.*  ***Note: This section will be used to monitor the progress of the study and the milestones will be subject to review by NHIC during the grant periods. The progress of a project is a critical pre-requisite for the continued disbursement of funds.*** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Project Milestones/Deliverables | M  1 | M  2 | M  3 | M  4 | M  5 | M  6 | M  7 | M  8 | M  9 | M  10 | M  11 | M  12 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |
| --- |
| **10. EXPECTED OUTCOMES**  *Please indicate your* ***realistic*** *expectations on the outcomes of the I2D Grant by providing the projected number/value of each listed KPI that you will aim to achieve during and after grant ended.*  *Please state ‘NA’ where indicator is not applicable.*  ***\*NHIC places special emphasis on these targets - you will need to satisfy at least two of these in order to be funded.***  ***NB: Number of licenses refers to the assignment of rights to use an IP for commercial purposes resulting in economic and societal benefits.***  ***Total licensing revenue includes (i) upfront/one-time payments; (ii) recurring revenue from royalty bearing IP licenses; (iii) licensing revenue from EULA; and (iv) Number of spin-offs refers to spin-offs that demonstrate successful market validation; spin-offs must be launched on the back of an IP/technology.*** |

|  |  |  |
| --- | --- | --- |
| KPI Category | Performance Indicators | Projected number/ value |
| Human Capital | Number of FTE trained in translational work under this Project |  |
| Intellectual Capital | Number of Invention Disclosures filed\* |  |
| Number of Patents applications filed\* |  |
| Number of Patents granted\* |  |
| Number of Patents commercialized/licensed\* |  |
| Journal Publication/Books (To state impact factor) |  |
| Presentations at international conferences |  |
| Awards for research at national and international level |  |
| Industry Relevance | Amount of Industry dollars received for this Project (cash contribution)\* |  |
| Amount of Industry dollars received for this project (in-kind contribution)\* |  |
| Number of Licences\* |  |
| Amount of Product sales revenue generated by licensees |  |
| Number of Spin-off/Start-up companies registered\* |  |
| Amount of investment raised by Spin-off/Start-up |  |
| Amount of Total Licensing revenues received. |  |
| Number of Option to license agreements executed |  |
| Project adopted by the healthcare system |  |
| Follow on funding awarded from public funding |  |
| New products or processes commercialized/deployed\* |  |

|  |
| --- |
| 1. **PRIOR FUNDING FOR TECHNOLOGY’S DEVELOPMENT**   *Please provide the following details for funding from all sources that has contributed to the development of the Technology. List the funding source, the PI and the outcome of the grant. Attach additional pages if necessary.* |

|  |
| --- |
| **11a. Support from any industry partner(s)**  *Please provide details on the funding or other resources provided to the Development Plan by any participating industry partner(s).* |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Items Supported** | **Source of Support** | **Form of Support** | | **Support Period** |
| **In-Kind[[9]](#footnote-9)**  **(Yes/No)** | **Cash Contribution[[10]](#footnote-10) (SGD)** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

|  |
| --- |
| **11b. List all grants applied for (e.g. NMRC, NRF, A\*STAR, MOE, Clusters, etc.) where outcome is pending**  *For all NMRC grant applications, please indicate application ID. Please indicate all the grants applied of similar proposal where the applicant is involved as PI, Co-PI, Co-Investigator or Collaborator and provide any overlapping sections in the proposals as an Annex.* |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Title of Research and PI’s role in project** | **Application ID** | **Funding Agency** | **Amount of fund applied for ($)** | **Support Period**  **(Year)** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

***Highlight if there is any potential overlap of the above funding with this application to NHIC. Note that double-***

***dipping is strictly prohibited. For any overlap, please explain how it would be handled.***

|  |
| --- |
| 1. **SUGGESTED REVIEWERS**   *Please suggest a minimum of two local reviewers, preferably not in the same institution. Note that they should not have any conflict of interest with or involvement in the proposed project. NHIC has the final decision on the selection of reviewers for the evaluation of the proposal.* |

|  |  |  |  |
| --- | --- | --- | --- |
| **Name of Reviewer** | **Organisation** | **Business Email** | **Relationship to PI and/or Co-I (s)** |
|  |  |  |  |
|  |  |  |  |
| **Remarks:** | | | |

|  |
| --- |
| 1. **TEAM MEMBERS**   **Attach the CV of each member of the research team.**  *Please use the format below and indicate NA if the required information is not applicable* ***(limit to 3 pages).*** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Name | : |  | Title | : |  |
| Email | : |  | Contact No | : |  |
| Nationality | : |  | Registered *with SMC/SDC[[11]](#footnote-11)* | : | *Yes*  *No* |

|  |
| --- |
| Current Position(s)  (provide full details, e.g. joint appointments, other academic appointments including those outside of Singapore) |

|  |
| --- |
| Percentage of time spent in Singapore every year: |

|  |
| --- |
| Employment History |

|  |
| --- |
| Academic qualifications (Indicate degree title, award year and institution name) |

|  |
| --- |
| Research interests |

|  |
| --- |
| Publications in last 5 years (include only publications of direct relevance to study, stating impact factors) |

|  |
| --- |
| Patents held (related or unrelated to study) |

|  |
| --- |
| Scientific Awards |

|  |
| --- |
| Half page summary of research outcomes from all previous grants [eg. publications (full papers only for past 5 years and highlight papers relevant to study), patents, awards, etc]. |

|  |
| --- |
| For Co-Is and Collaborators, please include: |
| Peer reviewed funding awarded as PI in last 5 years (from local and foreign agencies)   * Grant quantum, start and end date, funding agency and field of research | |

|  |
| --- |
| For Co-Is and Collaborators, please include: |
| * Current and previous support from NHIC, NMRC or other sources (include proposals pending approval) | |

|  |
| --- |
| 1. **SIGNATORIES**   In submitting the NHIC I2D Grant Application, the Principal Investigator, Co-Investigator(s), Collaborator(s) and Host Institution/Healthcare Cluster UNDERTAKE, on any Grant Award, to:   * Declare that all information is accurate and true. * Declare that he/she is free from any financial conflicts of interest. * Not send similar versions or part(s) of this grant application to other agencies for funding. * Be actively engaged in the execution of the research and comply with all laws, rules and regulations pertaining to safety, animal and human ethics, including the Singapore Good Clinical Practice guidelines. * Ensure that the requested equipment/resources are not funded by another agency or research proposal. * Ensure that there is a reasonable effort in accessing available equipment/resources within the host institution or elsewhere within Singapore. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Principal Investigator** |  |  |  |
| **Name** | | **Signature/date** |
| **Co-I/Collaborator\*** |  |  |  |
| **Name** | | **Signature/date** |
| **Co-I/Collaborator\*** |  |  |  |
| **Name** | | **Signature/date** |
| **Co-I/Collaborator\*** |  |  |  |
| **Name** | | **Signature/date** |

*\*Please add more rows or attach additional signatory pages if required.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Endorsed by:** | | | |
| **Director of Institution[[12]](#footnote-12)** |  |  |  |
| **Name** |  | **Signature/date** |

1. Definition of Principal Investigator (PI): The researcher who has the appropriate level of authority and the responsibility to **direct the research project** being supported by the grant. He/she is **responsible and accountable for the proper** **conduct** of the research project. One PI is allowed per application. He/she must hold a primary appointment in a local public hospital / public health institution / national specialty centre / Academic Medical Centre and be salaried by the institution. [↑](#footnote-ref-1)
2. Definition of Co-Investigator (Co-I): An individual involved in the scientific development and execution of the project, typically devotes a higher percentage of effort to the project as compared to a collaborator and is considered key personnel. He/she need to hold at least an adjunct position in a local public institution. [↑](#footnote-ref-2)
3. Definition of Collaborator: An individual involved in the scientific development and execution of the project, and typically devotes a higher percent of effort to the project. Researchers from overseas institutions or private companies can only participate as Collaborators. [↑](#footnote-ref-3)
4. Collaborator(s) are not entitled to receive directly any portion of the grant. [↑](#footnote-ref-4)
5. Definition of Host Institution: the body or institution or administering organization named in the Letter of Award as the “Host Institution” is the body responsible for undertaking and managing the Research and administering the Funding. [↑](#footnote-ref-5)
6. Represents percentage effort spent by the team members in the project relative to his/her other team members. The total in this column must add up to 100%. [↑](#footnote-ref-6)
7. Represents percentage effort spent by the team members on this project out of total work commitments (e.g. other grants, other teaching and administrative responsibilities, clinical work etc.) [↑](#footnote-ref-7)
8. [**Guidelines for the Management of MOH/NMRC (Grantor) Funding Programmes**](http://www.nmrc.gov.sg/docs/default-source/list/guidelines-for-the-management-of-nmrc-funding-programmes.pdf) [↑](#footnote-ref-8)
9. Please delete as appropriate [↑](#footnote-ref-9)
10. Please specify amount [↑](#footnote-ref-10)
11. SMC/SDC refers to the Singapore Medical Council/Singapore Dental Council. [↑](#footnote-ref-11)
12. *If PI is the Director of Institution,* ***UNDERTAKING*** ***by the Director of Institution’s Reporting Officer is required.*** [↑](#footnote-ref-12)